KTX-955

• UNSPSC Description:

  KTX-955 is an antumor and effective IRAK4 degrader, with DC50 values of 5 nM and 130 nM for IRAK4 and Ikaros, respectively[1]. KTX-955 is composed of CRBN ligand (blue part) Pomalidomide (HY-10984) and target protein ligand (red part) IRAK4-IN-20 (HY-150735).

• Target Antigen:

  IRAK; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;PROTAC

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ktx-955.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1C2C(NC(CC2)=O)=O)C3=CC=CC(N[C@H]4C[C@@H](C4)OC5CCN(CC5)C[C@H]6CC[C@H](N7C=C8C(C=C(C(NC(C9=CC=CC(C(F)(F)F)=N9)=O)=C8)C(C)(O)C)=N7)CC6)=C3C1=O

• Molecular Weight:

  884.94

• References & Citations:

  [1]Matthew Weiss. Discovery and characterization of IRAKIMiDs: degraders targeting both IRAK4 and IMiD substrates for oncology indications. Northeastern Section, ACS (NESACS).|[2]Nello Mainolfi, et al. Irak degraders and uses thereof. WO2020264499A1

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2573302-50-6